# EDGAR Filing Document

**Accession Number:** 0001745999
**File Stem:** 0000899243-23-009751
**Filing Date:** 2023-3
**Character Count:** 9708
**Document Hash:** 7f73aba0140eedb830b66a9a22103a93
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899243-23-009751.hdr.sgml**: 20230327

**ACCESSION NUMBER**: 0000899243-23-009751

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230316

**FILED AS OF DATE**: 20230327

**DATE AS OF CHANGE**: 20230327

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Simon Amy
- **CENTRAL INDEX KEY:** 0001963879

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39208
- **FILM NUMBER:** 23765747

**MAIL ADDRESS:**
- **STREET 1:** BEAM THERAPEUTICS, INC.
- **STREET 2:** 238 MAIN STREET, 9TH FL.
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Beam Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001745999
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 26 LANDSDOWNE STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 857-327-8775

**MAIL ADDRESS:**
- **STREET 1:** 26 LANDSDOWNE STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

## Ex-24

```
<PRE>
                           LIMITED POWER OF ATTORNEY

       The undersigned hereby constitutes and appoints John Evans, Terry-Ann
Burrell, and Christine Bellon, and each of them individually, with full power of
substitution, as the undersigned's true and lawful attorney-in-fact to:

       (1)   prepare, execute in the undersigned's name and on the undersigned's
             behalf, and submit to the U.S. Securities and Exchange Commission
             (the "SEC") a Form ID, including amendments thereto, and any other
             documents necessary or appropriate to obtain codes and passwords
             enabling the undersigned to make electronic filings with the SEC
             ofreports required by Section 16(a) of the Securities Exchange Act
             of 1934, as amended, or any rule or regulation of the SEC;

       (2)   execute for and on behalf of the undersigned, in the undersigned's
             capacity as officer and/or director of Beam Therapeutics Inc. (the
             "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in
             accordance with Section 16(a) of the Securities Exchange Act of
             1934, as amended, and the rules thereunder;

       (3)   do and perform any and all acts for and on behalf of the
             undersigned that may be necessary or desirable to complete and
             execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete
             and execute any amendment or amendments thereto, and timely file
             such form with the SEC and any stock exchange or similar authority;
             and

       (4)   take any other action of any type whatsoever in connection with the
             foregoing that, in the opinion of each such attorney-in-fact, may
             be of benefit to, in the best interest of, or legally required by,
             the undersigned, it being understood that the documents executed
             by each such attorney-in-fact on behalf of the undersigned pursuant
             to this Power of Attorney shall be in such form and shall contain
             such terms and conditions as each such attorney-in-fact may approve
             in each such attorney-in-fact's discretion.

       The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that each such
attorney-in-fact, or each such attorney-in-fact's substitute or substitutes,
shall lawfully do or cause to be done by virtue of this power of attorney and
the rights and powers herein granted. The undersigned acknowledges that each
foregoing attorney-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended.

       This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D
or 13G with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the undersigned in a
signed writing delivered to each foregoing attorney-in-fact.

                  [Remainder of page intentionally left blank]

       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 22nd day of March, 2023

                                                     /s/ Amy Simon
                                                   -------------------
                                                   Name: Amy Simon
</PRE>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Simon Amy<br><sub>(Last) (First) (Middle)</sub><br>C/O BEAM THERAPEUTICS INC.<br>238 MAIN STREET<br><sub>(Street)</sub><br>CAMBRIDGE, MA 02142<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Beam Therapeutics Inc. [ BEAM ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-03-16 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Medical Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 65129<sup>(1)(2)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2031-03-31 | Common Stock | 79500 | $80.04 | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2032-01-31 | Common Stock | 30000 | $69.21 | D |  |
| Stock Option (Right to Buy) | <sup>(5)</sup> | 2032-06-30 | Common Stock | 10000 | $38.71 | D |  |
| Stock Option (Right to Buy) | <sup>(6)</sup> | 2033-01-31 | Common Stock | 40000 | $43.45 | D |  |

---

### Footnotes:

(1) Includes 44,813, 15,000 and 5,000 restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2019 Equity Incentive Plan on March 31, 2021, March 31, 2022 and June 30, 2022 respectively.

(2) Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Issuer through each vesting date. The March 31, 2021 RSUs grant was originally for 59,750 RSUs of which 14,937 RSUs have already vested.

(3) The option vests as to 25% on the first anniversary of the vesting commencement date, March 31, 2022, and at a rate of 2.78% each month thereafter until the option is fully vested.

(4) The option vests at a rate of 2.08% each month after January 31, 2022 until the option is fully vested.

(5) The option vests at a rate of 2.08% each month after June 30, 2022 until the option is fully vested.

(6) The option vests at a rate of 2.08% each month after January 31, 2022 until the option is fully vested.

**Remarks:**
Exhibit List: Exhibit 24 - Power of Attorney

**Signature:** By: /s/ Christine Bellon, Attorney-in-Fact  
**Date:** 2023-03-27

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**